Fig. 5. Antitumor performance induced by BT-CI NPs under ultrasound irradiation on 4T1 tumors. (a) Schematic therapeutic regimen of BT-Cl NPs in 4T1 tumor-bearing mice. (b and c) NIR-II fluorescence tracking and corresponding signal intensity analysis of BT-CI NPs in 4T1 tumor-bearing mice (n = 3). (d–f) Body weight variations, tumor growth curves, and photographs of excised tumors from different groups (*P < 0.05, one-way ANOVA). (g) H&E and TUNEL-stained tumor slices 14 days after the initial intravenous injection.
